Transpire Bio Announces Progress in Clinical Development with Initiation of a New Human Subject Study for Asthma and COPD Inhaled Drug Program
Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...
HealthDay on MSN10d
Study Compares Single-Inhaler Triple Therapies for Treatment of COPD
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
Amarillo Globe-News on MSN9h
What are Zephyr Valves? Groundbreaking COPD treatment brings hope to Panhandle patients
After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...
thecardiologyadvisor.com5d
In COPD, CV Events Increase With Use of Single-Inhaler Triple Therapy
Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.
Commonly prescribed medications can increase fall risk and related injuries in people with COPD
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...
The Financial Express1d
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
News Medical on MSN5d
The impact of fall-risk medications on injuries in COPD patients
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...
EurekAlert!6d
Commonly prescribed medications increase fall risk and related injuries in people with COPD
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new study.
Pharmaceutical Technology3d
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.